CN112292127A - 使用利鲁唑前药治疗共济失调 - Google Patents

使用利鲁唑前药治疗共济失调 Download PDF

Info

Publication number
CN112292127A
CN112292127A CN201880073828.6A CN201880073828A CN112292127A CN 112292127 A CN112292127 A CN 112292127A CN 201880073828 A CN201880073828 A CN 201880073828A CN 112292127 A CN112292127 A CN 112292127A
Authority
CN
China
Prior art keywords
ataxia
patient
riluzole
administered
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073828.6A
Other languages
English (en)
Chinese (zh)
Inventor
V·科里奇
R·伯曼
M·贝纳
G·利塔利恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiaohaifen Therapeutics Co ltd
Original Assignee
Baiaohaifen Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112292127(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baiaohaifen Therapeutics Co ltd filed Critical Baiaohaifen Therapeutics Co ltd
Publication of CN112292127A publication Critical patent/CN112292127A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880073828.6A 2017-11-12 2018-11-11 使用利鲁唑前药治疗共济失调 Pending CN112292127A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US62/584,856 2017-11-12
US201862717948P 2018-08-13 2018-08-13
US62/717,948 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
CN112292127A true CN112292127A (zh) 2021-01-29

Family

ID=66438598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880073828.6A Pending CN112292127A (zh) 2017-11-12 2018-11-11 使用利鲁唑前药治疗共济失调

Country Status (26)

Country Link
US (3) US20210023061A1 (enExample)
EP (2) EP4483956B1 (enExample)
JP (2) JP7352542B2 (enExample)
KR (2) KR20250034521A (enExample)
CN (1) CN112292127A (enExample)
AU (1) AU2018364749C1 (enExample)
BR (1) BR112020009173A2 (enExample)
CA (1) CA3082096A1 (enExample)
DK (1) DK3706739T3 (enExample)
ES (1) ES2996892T3 (enExample)
FI (1) FI3706739T3 (enExample)
HR (1) HRP20241675T1 (enExample)
HU (1) HUE070302T2 (enExample)
IL (1) IL274532B2 (enExample)
LT (1) LT3706739T (enExample)
MD (1) MD3706739T2 (enExample)
MX (2) MX2020004678A (enExample)
PH (1) PH12020550583A1 (enExample)
PL (1) PL3706739T3 (enExample)
PT (1) PT3706739T (enExample)
RS (1) RS66277B1 (enExample)
SG (1) SG11202004332XA (enExample)
SI (1) SI3706739T1 (enExample)
SM (1) SMT202500022T1 (enExample)
WO (1) WO2019094851A1 (enExample)
ZA (1) ZA202002626B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978158C (en) 2015-03-03 2022-04-12 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624A4 (en) * 2021-01-18 2024-11-20 Biohaven Therapeutics Ltd. USE OF RILUZOLE PRODRUGS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US20250101034A1 (en) * 2021-11-04 2025-03-27 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
CN120018855A (zh) * 2022-05-23 2025-05-16 拜奥海芬治疗学有限公司 治疗脊髓小脑性共济失调的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
WO1995001782A2 (en) 1993-07-09 1995-01-19 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
EP1001748B1 (en) 1997-07-25 2006-04-19 Alpex Pharma S.A. A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
RU2233654C2 (ru) 1998-11-20 2004-08-10 Ртп Фарма Инк. Диспергируемые стабилизированные фосфолипидом микрочастицы
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8048449B2 (en) 2005-12-27 2011-11-01 Jubilant Organosys Ltd. Mouth dissolving pharmaceutical composition and process for preparing the same
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8256233B2 (en) 2008-10-31 2012-09-04 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
杨涛: "《实用临床神经内科疾病诊断学》", vol. 1, 西安交通大学出版社, pages: 351 *

Also Published As

Publication number Publication date
ZA202002626B (en) 2025-02-26
MD3706739T2 (ro) 2025-02-28
KR20200103658A (ko) 2020-09-02
SG11202004332XA (en) 2020-06-29
CA3082096A1 (en) 2019-05-16
PH12020550583A1 (en) 2021-05-31
WO2019094851A1 (en) 2019-05-16
EP3706739A4 (en) 2021-08-04
SI3706739T1 (sl) 2025-03-31
US20230355592A1 (en) 2023-11-09
ES2996892T3 (en) 2025-02-13
KR20250034521A (ko) 2025-03-11
PL3706739T3 (pl) 2025-03-10
FI3706739T3 (fi) 2024-12-27
HRP20241675T1 (hr) 2025-02-14
HUE070302T2 (hu) 2025-05-28
US20210023061A1 (en) 2021-01-28
EP4483956B1 (en) 2025-12-31
AU2018364749C1 (en) 2024-02-15
IL274532B1 (en) 2024-01-01
AU2018364749A1 (en) 2020-07-02
LT3706739T (lt) 2024-12-27
JP7352542B2 (ja) 2023-09-28
JP2023175823A (ja) 2023-12-12
PT3706739T (pt) 2024-12-04
JP2021502392A (ja) 2021-01-28
AU2018364749B2 (en) 2023-11-09
EP4483956A2 (en) 2025-01-01
RS66277B1 (sr) 2025-01-31
US12102618B2 (en) 2024-10-01
EP4483956A3 (en) 2025-03-19
IL274532B2 (en) 2024-05-01
EP3706739B1 (en) 2024-10-16
NZ765220A (en) 2023-11-24
IL274532A (en) 2020-06-30
EP3706739A1 (en) 2020-09-16
MX2023012640A (es) 2023-11-08
US20230390252A1 (en) 2023-12-07
SMT202500022T1 (it) 2025-03-12
MX2020004678A (es) 2020-08-13
BR112020009173A2 (pt) 2020-11-03
DK3706739T3 (da) 2024-12-02

Similar Documents

Publication Publication Date Title
US12102618B2 (en) Use of riluzole prodrugs to treat ataxias
Frederiksen et al. Corpus callosum tissue loss and development of motor and global cognitive impairment: the LADIS study
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
Menkes Heredodegenerative diseases
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
KR20240038980A (ko) 파킨슨병 및/또는 루이체 질환 또는 장애(들)의 치료 방법
WO2024216046A1 (en) Methods of treating anhedonia
JPWO2019241503A5 (enExample)
TW202038955A (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
HK40037184A (en) Use of riluzole prodrugs to treat ataxias
HK40118245A (en) Use of riluzole prodrugs to treat ataxias
HK40033906B (en) Use of riluzole prodrugs to treat ataxias
EA049071B1 (ru) Применение пролекарств рилузола для лечения атаксии
HK40033906A (en) Use of riluzole prodrugs to treat ataxias
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
JP6738797B2 (ja) レット症候群治療薬
CN119546294A (zh) 使用CNS渗透性sGC刺激剂治疗线粒体疾病Zagociguat
WO2025194109A1 (en) Compositions and methods for improving brain function
Ng et al. Motor neuron disease: causes, classification and treatments
Semnic et al. Structural MR Imaging in Movement Disorders
Drachman et al. Neurological Assessment in Aging
Novick et al. 0428 EFFECTIVENESS OF ANTIPSYCHOTIC TREATMENT IN NEVER TREATED PATIENTS WITH SCHIZOPHRENIA: 36-MONTH RESULTS FROM THE SCHIZOPHRENIA OUTPATIENTS HEALTH OUTCOMES (SOHO) STUDY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037184

Country of ref document: HK